Fresh SOY ISOFLAVONE EXTRACT - SOY ISOFLAVONES help in
lowering cholesterol and reducing the risk of heart disease.
Each capsule contains 33 mg Genistein and 76 mg Daidzein.
SOY ISOFLAVONES have been in the news recently for their known help in lowering cholesterol and reducing the risk of heart disease. This supplement is also important for prostate health. The main constituents in soy that are helpful are genistein and daidzein. These are NOT "phytoestrogens" as many so-called experts will allege as there is no estrogen, or testosterone, progesterone, DHEA, melatonin in any plant.
Studies on prostate health and isoflavones have been published in journals such as Prostate, Anticancer Research, Journal of Endoctrinology and many others. The proof is overwhelming.
Read a Summary of the evidence recently published by the National Institutes of Health:
Genistein is a phytochemical found in soybeans. Soybeans contain a variety of phytochemicals, and in particular they are the only source with nutritionally significant amounts of one type of phytochemical called isoflavones.
Foods that contain large amounts of soy are tofu, soy milk, and miso. In soy consuming populations, the concentrations of genistein average 0.28 ï¿½M, which is ten-fold higher than that seen in non-soy consuming populations. Much interest has been shown recently in genistein as a chemopreventive agent in prostate cancer. Both epidemiological and migrant studies have demonstrated a correlation between increased isoflavone levels in the serum and urine of Asian men with decreased levels of prostate cancer. Also, in a cross-national study for which data was available from 42 countries, soy products were identified as having a significant protective effect against prostate cancer.
Genistein is a potent inhibitor of protein-tyrosine kinase and topoisomerase II, enzymes which are crucial to cellular proliferation. Genistein is also an inhibitor of angiogenesis and several steroid metabolizing enzymes, such as aromatase and 5 alpha-reductase. A NCI-sponsored placebo-controlled clinical trial, Phase I Randomized Study of Genistein in Patients with Stage III or IV Prostate Cancer, has been underway since December 1999 to determine the safety and pharmacokinetics of genistein.